NEALS Members Attend the American Academy of Neurology Annual Meeting in Philadelphia
May 8, 2014
The 66th American Academy of Neurology Annual Meeting was held April 26th-May 3rd at the Pensylvania Convention Center in Philadelphia, PA.
NEALS was well represented at the 2014 AAN. The NEALS membership held a lunchtime satellite meeting on Tuesday, April 29th; membership topics discussed included an overview and discussion of proposed cIRB and Master Clinical Trial Agreement pilot projects, a call for NEALS Annual Meeting Abstract Review Committee volunteers, and several NEALS-affiliated trial updates given by trial PI's. Additionally, several abstracts featured NEALS-affiliated clinical research, and a number of NEALS members gave presentations during the plenary sessions. More than 2,500 abstracts featuring the latest scientific research were presented at the AAN meeting (you may browse the abstracts here: http://www.abstracts2view.com/aan/).
Some of the NEALS members who presented during the scientific sessions included:
Jeremy Shefner (SUNY Upstate), The Effect of Tirasemtiv on Functional Status in Patients with ALS;
Robert Miller (CPMC), Amyotrophic Lateral Sclerosis Quality Measures;
Rup Tandan (University of Vermont), Prospective Study of Cost of Care at Multidisciplinary Centers Adhering to AAN Amyotrophic Lateral Sclerosis (ALS) Practice Parameters;
Brent Morrison (JHU), Monocarboxylate Transporter 1 (MCT1) is Critical for Regeneration in Peripheral Nerves;
Alex Sherman (MGH), NeuroBANK™ and Global Unique Patient Identifier Allow for Secure Collaboration, Data Aggregation and Sharing.
Dr. Jeremy Shefner, NEALS Co-Founder and Former Co-Chair, received the Sheila Essey Award for ALS Research on May 1st. Since 1996, The ALS Association and the American Academy of Neurology (AAN) have presented this prestigious award to honor and acknowledge an individual who is making significant contributions in research for ALS. Dr. Shefner, of SUNY Upstate Medical University, has served as a principal investigator for numerous ALS trials, and his work in developing outcome measures to improve the ability to develop treatments for people with ALS has been instrumental in the field. Shefner served as a co-chair to the Northeast ALS Consortium for 18 years.